Background. Recent advances in rational adjuvant design and antigen selection have
enabled a new generation of vaccines with potential to treat and prevent infectious disease …

Fifty years after the introduction of the first effective antimicrobial agents against
Mycobacterium tuberculosis, this pathogen continues to be a tremendous public health …

An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …

Mycobacterium tuberculosis (M. tb) has led to approximately 1.3 million deaths globally in
2020 according to the World Health Organization (WHO). More effective treatments are …

It is estimated that one third of the world's population is infected with Mycobacterium
tuberculosis (Mtb). This astounding statistic, in combination with costly and lengthy treatment …

Tuberculosis (TB) remains one of the leading causes of death worldwide due to a single
infectious disease agent. BCG, the only licensed vaccine against TB, offers limited protection …

Chemotherapeutic intervention remains the primary strategy in treating and controlling
tuberculosis (TB). However, a complex interplay between therapeutic and patient-related …

An effective protein-based vaccine for tuberculosis will require a safe and effective adjuvant.
There are few adjuvants in approved human vaccines, including alum and the oil-in-water …

Tuberculosis (TB) vaccine development is hindered by the lack of clear surrogate markers of
protective human immunity to Mycobacterium tuberculosis. This study evaluated the …

Tuberculosis (TB), caused by Mycobacterium tuberculosis is the world's deadliest bacterial
infection, resulting in more than 1.4 million deaths annually. The emergence of drug …